Affiliation:
1. “George Emil Palade” University of Medicine, Pharmacy, Science and Technology , Târgu Mureș , Romania
2. Clinic of Cardiology, County Clinical Emergency Hospital , Târgu Mureș , Romania
3. Center of Advanced Research in Multimodality Cardiac Imaging, Cardio Med Medical Center , Târgu Mureș , Romania
Abstract
Abstract
Introduction: Systemic inflammation plays a key role in the pathophysiology of acute coronary syndrome (ACS), having a direct effect in promoting the progression and rupture of vulnerable coronary plaques. The aim of this study was to investigate the association between inflammatory biomarkers and the type of ACS (ST-elevation myocardial infarction – STEMI, non-ST-elevation myocardial infarction – NSTEMI, or unstable angina – UA) in patients with confirmed heart failure.
Material and Methods: This study included a total of 266 patients admitted to the Clinical Department of Cardiology of the County Emergency Clinical Hospital of Târgu Mureș – Cardiac Intensive Care Unit (CICU) for ACS of various types (UA, NSTEMI or STEMI) between January 1, 2017 and December 31, 2020, in whom the diagnosis of heart failure was established based on clinical and paraclinical data. From the total number of patients, 36 were hospitalized for UA and 230 for MI, of which 165 were STEMI and 65 were NSTEMI.
Results: Only hs-CRP and IL-6 were significantly higher in MI compared to UA. Mean hs-CRP was 4.9 ± 4.5 mg/mL in patients with UA vs. 20.4 ± 42.2 mg/mL in patients with MI (p = 0.001), and mean IL-6 was 7.2 ± 13.8 pg/mL in UA vs. 31.6 ± 129.2 pg/mL in MI (p <0.0001). ICAM seems to have had a greater discriminating power between STEMI and other types of ACS in those with heart failure, having a value more than double in those with STEMI (216.1 ± 149.6 ng/mL vs. 448.2 ± 754.4 ng/mL, p <0.0001).
Conclusions: In patients with heart failure, the increase of inflammatory biomarkers such as hs-CRP is associated with the development of an acute myocardial infarction but not with its type. Adhesion molecules, especially ICAM, are elevated in patients with STEMI compared to other types of ACS, indicating a potential role of endothelial alteration in the development of an ACS when it adds to systemic inflammation linked to heart failure.
Reference17 articles.
1. 1. Ramakrishnan AV, Varghese TP, Vanapalli S, Nair NK, Mingate MD. Platelet activating factor: A potential biomarker in acute coronary syndrome? Cardiovascular Therapeutics. 2017;35:64-70.
2. 2. Ma CY, Xu ZY, Wang SP, Peng HY, Liu F, Liu JH, Ren FX. Change of Inflammatory Factors in Patients with Acute Coronary Syndrome. Chin Med J (Engl). 2018;131:1444-1449.
3. 3. Ong SB, Hernández-Reséndiz S, Crespo-Avilan GE, et al. Inflammation Following Acute Myocardial Infarction: Multiple Players, Dynamic Roles, and Novel Therapeutic Opportunities. Pharmacology & Therapeutics. 2018;186:73-87.
4. 4. Fang L, Moore XL, Dart AM, Wang LM. Systemic inflammatory response following acute myocardial infarction. Journal of Geriatric Cardiology. 2015;12:305-312.
5. 5. Nian M, Lee P, Khaper N, Liu P. Inflammatory Cytokines and Postmyocardial Infarction Remodeling. Circulation Research. 2004;94:1543-1553.